Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China

X Lu, Z Ning, Z Li, H Cao, X Wang - Intractable & rare diseases …, 2016 - jstage.jst.go.jp
Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of
mature T-and NK-cell neoplasms associated with poor outcomes and lack of standard and …

A new class of retinoids with selective inhibition of AP-1 inhibits proliferation

…, L Jong, JF Cameron, E Harlev, G Graupner, XP Lu… - Nature, 1994 - nature.com
RETINOIDS regulate many biological processes, including differen-tiation, morphogenesis
and cell proliferation 1–3 . They are also important therapeutic agents, but their clinical …

Retinoids selective for retinoid X receptor response pathways

JM Lehmann, L Jong, A Fanjul, JF Cameron, XP Lu… - Science, 1992 - science.org
Retinoids have a broad spectrum of biological activities and are useful therapeutic agents.
Their physiological activities are mediated by two types of receptors, the retinoic acid …

Thermal and electrical conductivity of monolithic carbon aerogels

X Lu, O Nilsson, J Fricke, RW Pekala - Journal of Applied Physics, 1993 - pubs.aip.org
The thermal and electrical conductivity of monolithic carbon aerogels was investigated at
room temperature. Results showed both the solid thermal conductivity and the electrical …

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo …

…, T Liu, J Gao, M Cristofanilli, Z Ning, X Lu - The Lancet …, 2019 - thelancet.com
Background Tucidinostat (formerly known as chidamide) is an oral subtype-selective
histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with …

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated …

…, DS Pan, J Zhang, M Dong, X Du, XP Lu - Cancer chemotherapy …, 2012 - Springer
Purpose Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of
the benzamide class currently under clinical development in cancer indications. This study …

[HTML][HTML] Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind …

…, Z Zhou, X Li, Y Xu, Z Ning, H Cao, D Pan, H Yao, X Lu… - Science Bulletin, 2021 - Elsevier
Chiglitazar (Carfloglitazar) is a novel non-thiazolidinedione (TZD) structured peroxisome
proliferator-activated receptor (PPAR) pan-agonist that has shown promising effects on …

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

…, HX Cao, GF Dou, ZY Meng, YK Shi, XP Lu… - Cancer chemotherapy …, 2012 - Springer
Purpose Chidamide (CS055/HBI-8000) is a new benzamide class of histone deacetylase
inhibitor with marked anti-tumor activity. This study reports the phase I results. Methods …

[HTML][HTML] Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Y Sun, JH Hong, Z Ning, D Pan, X Fu, X Lu… - Frontiers in …, 2022 - frontiersin.org
Histone deacetylase (HDAC) is one of the most characterized epigenetic modifiers, modulating
chromatin structure and gene expression, which plays an important role in cell cycle, …

Quantitative structure-activity relationship study of histone deacetylase inhibitors

A Xie, C Liao, Z Li, Z Ning, W Hu, X Lu… - … -Anti-Cancer Agents, 2004 - ingentaconnect.com
Histone deacetylases (HDACs) play a critical role in gene transcription and have become a
novel target for the discovery of drugs against cancer and other diseases. During the past …